Allogene Therapeutics, Inc.
ALLO · Nasdaq · United States
Share price · ALLO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALLO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-6.5%
Nothing announced by ALLO that day or the session before.
- 17 Nov 2026-7.8%
Nothing announced by ALLO that day or the session before.
- 10 Nov 2026-12.1%
- 6 Nov 2026-4.6%
- 2 Nov 2026-7.6%
Nothing announced by ALLO that day or the session before.
- 30 Jul 2026+8.8%
- 29 Jul 2026+9.0%
- 14 Apr 2026-25.5%
- Day beforeOther material event
- 23 Mar 2026+17.9%
Nothing announced by ALLO that day or the session before.
- 17 Feb 2026+20.0%
Nothing announced by ALLO that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALLO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
cemacabtagene ansegedleucelevents and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 16% |
| Sessions with no dated event | — | 83% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CD19Cell therapy | Non-Hodgkin Lymphoma Large B-Cell Lymphoma | |
| Phase 1 | BCMACell therapy | Multiple Myeloma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2029 (1)
February 2029 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $42M | $40M+ $264M short-term inv. | $50M-$36M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $4.6M | $31M | $49M+ $294M short-term inv. | $43M-$32M operating cash flow | report ↗ |
| 2026-Q1 | — | $32M | $41M+ $237M short-term inv. | $43M-$13M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $31M | $48M+ $214M short-term inv. | $41M-$30M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $40M | $63M+ $221M short-term inv. | $51M-$39M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $50M | $53M+ $238M short-term inv. | $60M-$53M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $45M | $62M+ $240M short-term inv. | $66M-$44M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $50M | $181M+ $274M short-term inv. | $66M-$64M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $52M | $61M+ $334M short-term inv. | $65M-$56M operating cash flow | report ↗ |
| 2023-Q3 | <$0.1M | $46M | $80M+ $396M short-term inv. | $61M-$56M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $62M | $165M+ $337M short-term inv. | $78M-$62M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $80M | $120M+ $361M short-term inv. | $99M-$67M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $64M | $85M+ $478M short-term inv. | $83M-$48M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $57M | $106M+ $394M short-term inv. | $75M-$43M operating cash flow | report ↗ |
| 2022-Q1 | $0.1M | $60M | $95M+ $365M short-term inv. | $80M-$68M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $59M | $199M+ $293M short-term inv. | $78M-$49M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $150M | $62M+ $199M short-term inv. | $48M-$149M operating cash flow | report ↗ |
Allogene Therapeutics reported revenue of $0M for fiscal 2025, a 100.0% YoY decline from $0.02M, with R&D spend of $150.15M, down 21.9% YoY. Cash and equivalents stood at $61.98M, and the company recorded a net loss of $190.89M, with a quarterly net burn of $190.89M.
The company continued advancing its three lead programs: cema-cel in the ALPHA3 trial for large B-cell lymphoma, ALLO-316 in renal cell carcinoma, and ALLO-329 in autoimmune disease. In August 2025, it discontinued the FCA lymphodepletion arm of ALPHA3 and ended ALLO-647 development following a Grade 5 treatment-related serious adverse event; the trial now proceeds with FC lymphodepletion and observation. Allogene plans to announce MRD clearance data from the ALPHA3 interim futility analysis in April 2026, expects initial proof-of-concept data from the ALLO-329 RESOLUTION trial in June 2026, and anticipates completing ALPHA3 enrollment by the end of 2027. The company is also exploring partnering opportunities for ALLO-316.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | <$0.1M | $192M | $86M+ $217M short-term inv. | $64M-$200M operating cash flow | report ↗ |
| 2023-FY | $0.1M | $243M | $93M+ $366M short-term inv. | $82M-$238M operating cash flow | report ↗ |
| 2022-FY | $0.2M | $256M | $72M+ $455M short-term inv. | $83M-$221M operating cash flow | report ↗ |
| 2021-FY | $38M | $220M | $184M+ $284M short-term inv. | $64M-$185M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 14 sales ($668K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M. · CHIEF FINANCIAL OFFICER | Open-market sale | 36,342 | $1.34 | $49K | Form 4 |
| 2026-08-21 | Douglas Earl Martin · SVP, General Counsel | Open-market sale | 29,697 | $2.12 | $63K | Form 4 |
| 2026-07-01 | Roberts Zachary · President and CEO | Award / grant (derivative) | 134,530 | — | — | Form 4 |
| 2026-07-01 | Roberts Zachary · President and CEO | Award / grant (derivative) | 476,190 | — | — | Form 4 |
| 2026-06-18 | Barrett Elizabeth A. · director | Award / grant (derivative) | 95,400 | — | — | Form 4 |
| 2026-06-18 | Humer Franz B · director | Award / grant (derivative) | 95,400 | — | — | Form 4 |
| 2026-06-18 | WITTE OWEN N. · director | Award / grant (derivative) | 95,400 | — | — | Form 4 |
| 2026-06-18 | SATO VICKI L · director | Award / grant (derivative) | 95,400 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 208 reporting institutions held 184.2M shares ($429.1M, 53.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Pfizer Inc | 22,032,040 | $49.8M |
| 2 | BlackRock, Inc. | 19,091,095 | $46.6M |
| 3 | TPG GP A, LLC | 18,716,306 | $45.7M |
| 4 | STATE STREET CORP | 8,660,306 | $21.1M |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 8,379,840 | $20.4M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 6,921,350 | $16.9M |
| 7 | CITADEL ADVISORS LLC | 6,793,620 | $16.6M |
| 8 | TWO SIGMA INVESTMENTS, LP | 5,375,456 | $13.1M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 4,124,178 | $10.1M |
| 10 | Frazier Life Sciences Management, L.P. | 3,796,668 | $9.3M |
| 11 | Woodline Partners LP | 3,501,078 | $8.5M |
| 12 | Patient Square Capital LP | 3,450,000 | $8.4M |
| 13 | MARSHALL WACE, LLP | 3,447,984 | $8.4M |
| 14 | MILLENNIUM MANAGEMENT LLC | 3,322,053 | $8.1M |
| 15 | Candriam S.C.A. | 2,997,318 | $7.3M |